TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Wiley-Blackwell
Fatty liver disease medication may have no effect
February 10th, 2009
A new randomized, prospective trial has shown that orlistat, a commonly prescribed inhibitor of fat absorption, does not help patients with fatty liver disease (FLD) lose weight, nor does it improve their liver enzymes or insulin resistance. These findings are in the January issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience (www.interscience.wiley.com). With obesity on the rise throughout the world, FLD has become a major epidemic. Weight loss improves liver enzymes and levels of fat in the liver, and the study did show...
Source: TB & Outbreaks Week (2009-02-10)
|
